Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW et al. Cancer Chemother Pharmacol. 2014 Nov 25. [Epub ahead of print].
Panobinostat: a review of trial results and future prospects in multiple myeloma.
Libby EN et al. Expert Rev Hematol. 2014 Nov 20:1-10. [Epub ahead of print].
Marizomib, a potent second generation proteasome inhibitor from natural origin.
Ma L et al. Anticancer Agents Med Chem. 2014 Nov 14. [Epub ahead of print].
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation.
Scheid C et al. Eur J Haematol. 2014 Nov 17. doi: 10.1111/ejh.12491. [Epub ahead of print].
Phase 2 study of carfilzomib, thalidomide and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
Sonneveld P et al. Blood. 2014 Nov 14. pii: blood-2014-05-576256. [Epub ahead of print].
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsedmultiple myeloma.
Kumar SK et al. Blood. 2014 Nov 13. pii: blood-2014-05-573741. [Epub ahead of print].
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Gupta N et al. Br J Clin Pharmacol. 2014 Nov 6. doi: 10.1111/bcp.12542. [Epub ahead of print]